Beyond its established role in PRL suppression, CAB demonstrated promising potential in reducing androgen excess, particularly in PCOS with elevated PRL cases, and improving clinical outcomes, without inducing notable changes in FSH or LH levels. This evidence concerns the gene BRD2 and hyperandrogenism.